Preferred Label : Letaplimab;
NCIt synonyms : Anti-CD47 Monoclonal Antibody IBI188;
NCIt definition : A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen
CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous
administration, letaplimab selectively binds to CD47 expressed on tumor cells and
blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein
expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates
the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling
mediated by the binding of calreticulin (CRT), which is specifically expressed on
the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein
(LRP), expressed on macrophages. This results in macrophage activation and the specific
phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an
anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing
tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells
from phagocytosis, which allows cancer cells to proliferate.;
UNII : BDN84I1TFE;
CAS number : 2283356-07-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2283356-07-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : IBI 188; IBI-188;
NCI Metathesaurus CUI : CL936985;
Origin ID : C157385;
UMLS CUI : C5446334;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
